|
||||||||||||||||||||||
|
|
Phase II Study of Anguidine Chemotherapy for Advanced Soft Tissue and Bony Sarcomas
Basic Trial Information
Objectives I. Determine the level of efficacy of the drug anguidine as a single agent in the treatment of advanced soft tissue and bony sarcomas in patients who have failed to respond or have relapsed on higher priority therapeutic regimens. II. Determine the toxicity of anguidine. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with histologically confirmed measurable lesions of primary or recurrent soft tissue or bony sarcoma not amenable to control by surgery, radiotherapy or higher priority chemotherapy. Patients must have recovered from prior therapy, which may not have included study agent. A life expectancy of at least 6 weeks, Karnofsky performance status of at least 50%, normal renal and hepatic functions and wbc above 3000, granulocytes above 2000 and platelets above 100,000 are required. Expected Enrollment Protocol closed 11/78. Outline Single-agent Chemotherapy. Anguidine, ANG, NSC-141537.Published Results Thigpen JT, Vaughn C, Stuckey WJ: Phase II trial of anguidine in patients with sarcomas unresponsive to prior chemotherapy: A Southwest Oncology Group Study. Cancer Treat Rep 65 (9-10): 881-2, 1981 Sep-Oct.[PUBMED Abstract] Trial Lead Organizations Southwest Oncology Group
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |